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To the editor,  1 
Hedgehog pathway inhibitors (HPI) inactivating SMO 1, have become first line treatment for 2 
patients with locally advanced BCC (laBCC). HPI safety and efficacy  have been shown in 3 
clinical trials2,3. Nevertheless, common adverse events lead to treatment discontinuation. 4 
Some laBCC develop acquired resistance (AR) to HPI, illustrated by tumor regrowth under 5 
treatment after an initial response. AR  is explained by the presence of SMO mutations  6 
affecting the binding of the drug or conferring constitutive activation of SMO , (acquired de 7 
novo or present before treatment at low frequency and selected during its course) 
4,5
. LaBCC 8 
patients who discontinued vismodegib after achieving complete remission (CR) frequently 9 
develop multifocal relapses, which could harbor vismodegib resistant mutations
6
. We 10 
hypothesized that vismodegib resistant clones could lie dormant and regrow after drug 11 
withdrawal.  12 
To this end, we studied three laBCC patients who achieved clinically and histologically CR 13 
with vismodegib and relapsed after treatment discontinuation. All patients gave their written 14 
informed consent for the study, including a non-opposition note and signed agreement for 15 
genetic analysis. Frozen or formalin-fixed paraffin-embedded (FFPE) tumor tissue was 16 
obtained before vismodegib treatment and after relapse for DNA extraction. DNA sequencing 17 
of 21 cancer genes (CDKN2A, CTNNB1, DHH, FBXW11, GLI1, GLI2, GLI3, GSK3B, 18 
HHIP, HRAS, IHH, NRAS, PIK3CA, PTCH1, PTCH2, SHH, SMO, STAT5B, STK36, 19 
SUFU, TP53) (in-house microarray) was performed using Next Generation Sequencing 20 
4 
 
(NGS) on PGM sequencer and ThermoFisher technology (Ion PGM™ Hi-Q™ View Chef 1 
Kit, ThermoFisher). The preparation of amplicon libraries was made by AmpliSeq. Average 2 
sequencing depth was 1125X, and 95% of the target regions were covered. Detection of 3 
variants was performed with integrated software dedicated to Ion Torrent technology (Torrent 4 
browser and Ion Reporter). Only variants with a high-quality score (p value <0.001) and 5 
allelic frequency of a least 0.05 of variant reads were retained.  6 
Multifocal relapses from three laBCC patients who achieved CR with vismodegib and 7 
discontinued treatment (Fig.1) were studied.  Driver mutations in HP genes were identified:  8 
Loss-of-Function PTCH1 mutations in patients 1 and 2 and Gain-of-Function  SMO W535L 9 
mutation in patient 3 (Table1). That latter was shown to confer partial drug resistance to 10 
vismodegib 
5
. However CR observed in this patient 3 as well as in 2 other patients with SMO 11 
W535L tumors  treated in our clinic (data shown) suggest another yet unidentified genomic 12 
variants could be implicated in the resistance. TP53 mutations were also observed in patients 13 
2 and 3 (Table 1). All identified mutations are most likely somatic, as they are present in only 14 
a fraction of cells (Variant Allele Frequency < 35%), and they inactivate the tumor suppressor 15 
gene PTCH1 or are reported as cancer mutations in the COSMIC database. Another variant 16 
not described in BCC was detected in patient 2 in gene hFU (STK36), a positive regulator of 17 
the GLI zinc-finger transcription factors 7. We found no significant differences in the coding 18 
regions of sequenced genes in relapsed tumors compared to pre-treatment tumors, especially, 19 
no additional SMO mutations (Table1).  20 
5 
 
Our results suggest that in laBCC, multifocal relapses after vismodegib discontinuation harbor 1 
the same mutational pattern than the baseline tumor. These results are interesting as BCCs are 2 
amongst the most highly mutated human cancers and could be expected to select drug 3 
resistant clones. This suggests that residual disease, after treatment cessation, regrows without 4 
the need to acquire further genetic alterations  and could be eligible for treatment rechallenge. 5 
Accordingly, two of our patients who presented multifocal relapses after treatment 6 
discontinuation including the one bearing a SMO mutation were again subjected to 7 
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Tables and figures legends: 10 
Patients Patient 1+ Patient 1 ++ Patient 2++ Patient 3+ 
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Table 1 : NGS analysis of patient’s tumor at baseline and at relapse after drug 14 
discountinuation. 15 
 * =  Stop codon, +Frozen biopsy, ++ FFPE biopsy, R=Relapse. The percentages (%) 16 
correspond to the presence of mutation in the tumor 17 




Figure 1: 2 
 Illustration of a laBCC and its multifocal relapses in one of the studied patients, a)- Baseline 3 
invasive basal cell carcinoma of the upper right eyelid, b)- Complete tumoral remission after 4 
12 months of Vismodegib treatment, c)- Multifocal relapses (indicated by arrows) 1 year after 5 
treatment discontinuation..  6 
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